Social value of a quality-adjusted life year (QALY) in Spain: the point of view of oncologists-Reference-Cited by-同舟云学术

Social value of a quality-adjusted life year (QALY) in Spain: the point of view of oncologists

Published:2014-06-13 Issue:10 Volume:16 Page:914-920
ISSN:1699-048X
Container-title:Clinical and Translational Oncology
language:en
Short-container-title:Clin Transl Oncol

Author:

Camps-Herrero C.,Paz-Ares L.,Codes M.,López-López R.,Antón-Torres A.,Gascón-Vilaplana P.,Guillem-Porta V.,Carrato A.,Cruz-Hernández J. J.,Caballero-Díaz C.,Blasco-Cordellat A.,Moreno-Nogueira J. A.,Díaz-Rubio E.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s12094-014-1170-1.pdf

Reference28 articles.

1. Darba J. Pharmaceutical expenditure and therapeutic value of new medicines in Spain. Pharmacoeconomics. 2003;21(16):1211–2.

2. Pazdur R. Endpoints for assessing drug activity in clinical trials. Oncologist. 2008;13:19–21.

3. Sargent D. What constitutes reasonable evidence of efficacy and effectiveness to guide oncology treatment decisions? Oncologist. 2009;15:19–23.

4. Ocaña A, Tannock IF. When are “positive” clinical trials in oncology truly positive? J Natl Cancer Inst. 2011;103:16–20.

5. Sobrero A, Bruzzi P. Incremental advance or seismic shift? The need to raise the bar of efficacy for drug approval. J Clin Oncol. 2009;27:5868–73.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. International Cost-Effectiveness Analysis of Durvalumab in Stage III Non–Small Cell Lung Cancer;JAMA Network Open;2024-05-30

2. ¿Qué es una intervención sanitaria eficiente en España en 2020?;Gaceta Sanitaria;2020-03

3. An Easy Way for Clinical Validation of the Pharmacoeconomic Model in Dupuytren Disease;Dupuytren Disease and Related Diseases - The Cutting Edge;2016-09-07

4. The Value of Medicines: A Crucial but Vague Concept;PharmacoEconomics;2016-07-21

5. Terminal cancer drug treatment? Need for a simple cost-benefit measure;Journal of Cancer Policy;2015-12